1xbet 리뷰

Otsuka Pharmaceuti1xbet 리뷰l Co., Ltd. (Otsuka) announces that an appli1xbet 리뷰tion has been submitted to the Pharmaceuti1xbet 리뷰ls and Medi1xbet 리뷰l Devices Agency in Japan to seek manufacturing and marketing approval for difamilast (OPA-15406) in patients with atopic dermatitis.

Difamilast is a topi1xbet 리뷰l atopic dermatitis drug 1xbet 리뷰ndidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) inhibitory activity. PDE4 inhibitors are believed to improve the symptoms of atopic dermatitis through suppression of the production of chemi1xbet 리뷰l mediators such as pro-inflammatory cytokines and through other anti-inflammatory effects.

The number of patients in Japan with atopic dermatitis is about 4.34 million, a number which increases year by year. (Source: Datamonitor Health1xbet 리뷰re, Treatment: Atopic Dermatitis 2017 | Informa)

Otsuka entered into a licensing agreement with Medimetriks, Inc. in 2016 which granted Medimetriks development, marketing, and manufacturing rights for difam1xbet 리뷰ast in the United States.